The estrogen patch: every brand, every generic, and why yours is out of stock

What is an estrogen patch and how does it work?

Modern estradiol patches are matrix systems: the hormone is dissolved directly in the adhesive layer, so the patch is thin, flexible, and delivers a controlled dose per day — standard strengths run 0.025 to 0.1 mg/day. You apply it to clean, dry skin on the lower abdomen or buttocks (not the breasts, per labeling), and rotate sites. The transdermal route matters clinically for one big reason: estrogen absorbed through the skin enters circulation directly instead of passing through the liver first, the way a swallowed pill does. That avoids the first-pass effect that drives up clotting factors — the mechanism behind the observational finding that transdermal estrogen carries lower venous-thromboembolism risk than oral. It also means steadier blood levels than the daily peak-and-trough of a pill. The trade-offs are mundane: skin irritation at the site, patches peeling in heat or heavy sweat, and — in 2026 — the small matter of actually finding one in stock.

Sources: FDA-approved estradiol transdermal labeling via DailyMed (NIH); route-of-administration evidence per The Menopause Society 2022 hormone therapy position statement.

Which estrogen patch brands exist?

Six names cover nearly every prescription. The practical differences are schedule (once vs twice weekly), whether a generic exists, and — right now — whether it's on the shortage list.

Sources: product labeling via DailyMed; shortage status per the ASHP estradiol transdermal system entry and manufacturer reporting via NBC News, May 10, 2026. Doses within a brand go in and out of stock individually — check the ASHP entry for your exact strength.

Is generic the same as brand? (Dotti vs Vivelle-Dot)

Yes, in the way that matters. Dotti and Lyllana are FDA-approved generic estradiol transdermal systems referencing Vivelle-Dot — approved as therapeutically equivalent, same hormone, same delivery rate, same twice-weekly schedule. The FDA's equivalence rating system exists precisely so your pharmacist can substitute one for the other without calling your prescriber. Two honest caveats. First, adhesives and backing materials differ between manufacturers, and some women genuinely find one patch stays on better or irritates less than another — an annoyance, not a safety issue. Second, equivalence doesn't help when the entire reference family is short: Vivelle-Dot, Dotti, and Lyllana doses have all appeared on the ASHP list in 2026, so "just take the generic" is frequently not an option at the counter. That's when switching schedule (to a once-weekly Climara-family patch) or switching route entirely becomes the conversation to have with your prescriber.

Source: FDA therapeutic-equivalence framework via Drugs@FDA (search any patch brand for its approval and equivalence records).

Why is my estrogen patch out of stock?

Demand outran manufacturing. After the FDA removed HRT's black-box warnings (announced November 2025, labels changed February 2026), patch prescriptions — already climbing — spiked. ASHP has listed estradiol patch products from Amneal, Zydus, Sandoz, Noven, and Viatris as short since January 2026, while the FDA has not declared a formal shortage. Supply estimates range from "improving by end of 2026" (Mayo Clinic's Dr. Stephanie Faubion) to "up to three years" (unnamed industry sources via Reuters).

Which telehealth providers prescribe the patch — and at what price?

Every women's platform we track that offers a patch route, ordered by our methodology score — not by who pays us. During the shortage, the practical advantage of these platforms is a clinician one message away when a rewrite to a different brand, dose, or route is needed.

We earn a commission when readers sign up with some of these platforms — disclosed on every page, never a factor in scores or order. Full comparison on the rankings; full price math on the cost page.

Patch, pill, or gel — how do they compare?

All three deliver systemic estradiol; the differences are route and ritual. Patch: steady transdermal delivery, once/twice-weekly, the lower-observed clot-risk route — currently supply-constrained. Pill: cheapest (verified from $39.99/mo at Alloy), daily, first-pass liver metabolism with its small added clot risk — generally avoided in women with clot history. Gel or spray:transdermal like the patch, daily application, no adhesive issues, in better supply during the shortage ($69.99/mo verified at Alloy). The Menopause Society's position statement treats route selection as an individualized decision based on your risk profile and preference — which in plain English means: all three are legitimate, and the right one is the one you'll actually use consistently and can actually fill.

Source: The Menopause Society 2022 hormone therapy position statement.